Based on assay design and coverage of key intronic regions of the genome, we were also able to detect a broad range of clinically relevant fusions, such as EML4::ALK, RET, and ROS1 rearrangements with diverse gene partners in lung carcinomas, BRAF::KIAA1549 and EGFRvIII alterations in gliomas (Fig. 1b and c). This evidence concerns the gene EML4 and glioma.